期刊文献+

Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients 被引量:23

Effect of clinician-patient communication on compliance with flupentixol-melitracen in functional dyspepsia patients
下载PDF
导出
摘要 AIM: To explore whether clinician-patient communication affects adherence to psychoactive drugs in functional dyspepsia(FD) patients with psychological symptoms. METHODS: A total of 262 FD patients with psychological symptoms were randomly assigned to four groups. The patients in Groups 1-3 were given flupentixol-melitracen(FM) plus omeprazole treatment. Those in Group 1 received explanations of both the psychological and gastrointestinal(GI) mechanisms of the generation of FD symptoms and the effects of FM. In Group 2, only the psychological mechanisms were emphasized. The patients in Group 3 were not given an explanation for the prescription of FM. Those in Group 4 were given omeprazole alone. The primary endpoints of this study were compliance rate and compliance index to FM in Groups 1-3. Survival analyses were also conducted. The secondary end points were dyspepsia and psychological symptom improvement in Groups 1-4. The correlations between the compliance indices and the reductions in dyspepsia and psychological symptom scores were also evaluated in Groups 1-3.RESULTS: After 8 wk of treatment, the compliance rates were 67.7% in Group 1, 42.4% in Group 2 and 47.7% in Group 3(Group 1 vs Group 2, P = 0.006; Group 1 vs Group 3, P = 0.033). The compliance index(Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.024) with the FM regimen was significantly higher in Group 1 than in Groups 2 and 3. The survival analysis revealed that the patients in Group 1 exhibited a significantlyhigher compliance rate than Groups 2 and 3(Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.018). The improvement in dyspepsia(Group 1 vs Group 2, P < 0.05; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01) and psychological symptom scores(anxiety: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01; depression: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.01; Group 1 vs Group 4, P < 0.01) in Group 1 were greater than those in Groups 2-4. The compliance indices were positively correlated with the reduction in symptom scores in Groups 1-3. CONCLUSION: Appropriate clinician-patient communication regarding the reasons for prescribing psychoactive drugs that emphasizes both the psychological and GI mechanisms might improve adherence to FM in patients with FD. AIM: To explore whether clinician-patient communication affects adherence to psychoactive drugs in functional dyspepsia(FD) patients with psychological symptoms. METHODS: A total of 262 FD patients with psychological symptoms were randomly assigned to four groups. The patients in Groups 1-3 were given flupentixol-melitracen(FM) plus omeprazole treatment. Those in Group 1 received explanations of both the psychological and gastrointestinal(GI) mechanisms of the generation of FD symptoms and the effects of FM. In Group 2, only the psychological mechanisms were emphasized. The patients in Group 3 were not given an explanation for the prescription of FM. Those in Group 4 were given omeprazole alone. The primary endpoints of this study were compliance rate and compliance index to FM in Groups 1-3. Survival analyses were also conducted. The secondary end points were dyspepsia and psychological symptom improvement in Groups 1-4. The correlations between the compliance indices and the reductions in dyspepsia and psychological symptom scores were also evaluated in Groups 1-3.RESULTS: After 8 wk of treatment, the compliance rates were 67.7% in Group 1, 42.4% in Group 2 and 47.7% in Group 3(Group 1 vs Group 2, P = 0.006; Group 1 vs Group 3, P = 0.033). The compliance index(Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.024) with the FM regimen was significantly higher in Group 1 than in Groups 2 and 3. The survival analysis revealed that the patients in Group 1 exhibited a significantlyhigher compliance rate than Groups 2 and 3(Group 1 vs Group 2, P = 0.002; Group 1 vs Group 3, P = 0.018). The improvement in dyspepsia(Group 1 vs Group 2, P < 0.05; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01) and psychological symptom scores(anxiety: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.05; Group 1 vs Group 4, P < 0.01; depression: Group 1 vs Group 2, P < 0.01; Group 1 vs Group 3, P < 0.01; Group 1 vs Group 4, P < 0.01) in Group 1 were greater than those in Groups 2-4. The compliance indices were positively correlated with the reduction in symptom scores in Groups 1-3. CONCLUSION: Appropriate clinician-patient communication regarding the reasons for prescribing psychoactive drugs that emphasizes both the psychological and GI mechanisms might improve adherence to FM in patients with FD.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第15期4652-4659,共8页 世界胃肠病学杂志(英文版)
基金 Supported by National Natural Science Foundation of China,No.81470812,No.81270463,No.31171106,and No.81070302(to Chen SL)
关键词 Functional DYSPEPSIA ANXIETY DEPRESSION Psychoactive DRUG COMPLIANCE Functional dyspepsia Anxiety Depression Psychoactive drug Compliance
  • 相关文献

参考文献31

  • 1Ghoshal UC, Singh R, Chang FY, Hou X, Wong BC, Kachintorn U.Epidemiology of uninvestigated and functional dyspepsia in Asia:facts and fiction. J Neurogastroenterol Motil 2011; 17: 235-244[PMID: 21860815 DOI: 10.5056/jnm.2011.17.3.235].
  • 2Van Oudenhove L, Aziz Q. The role of psychosocial factorsand psychiatric disorders in functional dyspepsia. Nat RevGastroenterol Hepatol 2013; 10: 158-167 [PMID: 23358396 DOI:10.1038/nrgastro.2013.10].
  • 3Wu JC. Psychological Co-morbidity in Functional GastrointestinalDisorders: Epidemiology, Mechanisms and Management. JNeurogastroenterol Motil 2012; 18: 13-18 [PMID: 22323984 DOI:10.5056/jnm.2012.18.1.13].
  • 4Mak AD, Wu JC, Chan Y, Chan FK, Sung JJ, Lee S. Dyspepsia isstrongly associated with major depression and generalised anxietydisorder - a community study. Aliment Pharmacol Ther 2012; 36:800-810 [PMID: 22957985 DOI: 10.1111/apt.12036].
  • 5Mahadeva S, Goh KL. Anxiety, depression and quality oflife differences between functional and organic dyspepsia. JGastroenterol Hepatol 2011; 26 Suppl 3: 49-52 [PMID: 21443710DOI: 10.1111/j.1440-1746.2011.06656.x].
  • 6Magni G, di Mario F, Bernasconi G, Mastropaolo G. DSM-IIIdiagnoses associated with dyspepsia of unknown cause. Am JPsychiatry 1987; 144: 1222-1223 [PMID: 3631325].
  • 7Hojo M, Miwa H, Yokoyama T, Ohkusa T, Nagahara A, KawabeM, Asaoka D, Izumi Y, Sato N. Treatment of functional dyspepsiawith antianxiety or antidepressive agents: systematic review.J Gastroenterol 2005; 40: 1036-1042 [PMID: 16322947 DOI:10.1007/s00535-005-1687-8].
  • 8Saad RJ, Chey WD. Review article: current and emerging therapiesfor functional dyspepsia. Aliment Pharmacol Ther 2006; 24:475-492 [PMID: 16886913 DOI: 10.1111/j.1365-2036.2006.03005.x].
  • 9Lacy BE, Talley NJ, Locke GR, Bouras EP, DiBaise JK, El-SeragHB, Abraham BP, Howden CW, Moayyedi P, Prather C. Reviewarticle: current treatment options and management of functionaldyspepsia. Aliment Pharmacol Ther 2012; 36: 3-15 [PMID:22591037 DOI: 10.1111/j.1365-2036.2012.05128.x].
  • 10Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E,Robinson P. The role of the primary care physician in patients'adherence to antidepressant therapy. Med Care 1995; 33: 67-74[PMID: 7823648].

同被引文献219

引证文献23

二级引证文献286

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部